%0 Journal Article
%A McManus, Róisín M.
%A Latz, Eicke
%T NLRP3 inflammasome signalling in Alzheimer's disease
%J Neuropharmacology
%V 252
%@ 0028-3908
%C Amsterdam [u.a.]
%I Elsevier Science
%M DZNE-2024-00470
%P 109941
%D 2024
%X Every year, 10 million people develop dementia, the most common of which is Alzheimer's disease (AD). To date, there is no way to prevent cognitive decline and therapies are limited. This review provides a neuroimmunological perspective on the progression of AD, and discusses the immune-targeted therapies that are in preclinical and clinical trials that may impact the development of this disease. Specifically, we look to the role of the NLRP3 inflammasome, its triggers in the brain and how its activation can contribute to the progression of dementia. We summarise the range of inhibitors targeting the NLRP3 inflammasome and its downstream pathways that are under investigation, and discuss future therapeutic perspectives for this devastating condition.
%K Animals
%K Humans
%K Alzheimer Disease: metabolism
%K Alzheimer Disease: immunology
%K Alzheimer Disease: drug therapy
%K Brain: metabolism
%K Brain: immunology
%K Inflammasomes: metabolism
%K NLR Family, Pyrin Domain-Containing 3 Protein: metabolism
%K NLR Family, Pyrin Domain-Containing 3 Protein: antagonists & inhibitors
%K Signal Transduction: physiology
%K Signal Transduction: drug effects
%K Alzheimer's disease (Other)
%K Immune-targeted therapies (Other)
%K Microglia (Other)
%K NLRP3 inflammasome (Other)
%K Neuroimmunology (Other)
%K Preclinical models (Other)
%K Inflammasomes (NLM Chemicals)
%K NLR Family, Pyrin Domain-Containing 3 Protein (NLM Chemicals)
%K NLRP3 protein, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38565393
%R 10.1016/j.neuropharm.2024.109941
%U https://pub.dzne.de/record/269039